160 related articles for article (PubMed ID: 9740073)
1. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma.
Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
Cancer; 1998 Sep; 83(6):1094-101. PubMed ID: 9740073
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD44v6 is not a sensitive tumor marker in patients with head and neck squamous cell cancer.
Andratschke M; Chaubal S; Pauli C; Mack B; Hagedorn H; Wollenberg B
Anticancer Res; 2005; 25(4):2821-6. PubMed ID: 16080532
[TBL] [Abstract][Full Text] [Related]
4. Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6.
Weg-Remers S; Hildebrandt U; Feifel G; Moser C; Zeitz M; Stallmach A
Am J Gastroenterol; 1998 May; 93(5):790-4. PubMed ID: 9625129
[TBL] [Abstract][Full Text] [Related]
5. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
[TBL] [Abstract][Full Text] [Related]
6. Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer.
Yamane N; Tsujitani S; Makino M; Maeta M; Kaibara N
Oncology; 1999 Apr; 56(3):232-8. PubMed ID: 10202279
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD44v6 in advanced gastric cancer and its relationship to hematogenous metastasis and long-term prognosis.
Yamaguchi A; Goi T; Yu J; Hirono Y; Ishida M; Iida A; Kimura T; Takeuchi K; Katayama K; Hirose K
J Surg Oncol; 2002 Apr; 79(4):230-5. PubMed ID: 11920780
[TBL] [Abstract][Full Text] [Related]
8. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
[TBL] [Abstract][Full Text] [Related]
9. [Expression and clinical significance of CD44v6 and sCD44v6 in gastric carcinoma].
Zhou DH; Ma ZM; Chen Y
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):833-7. PubMed ID: 18396641
[TBL] [Abstract][Full Text] [Related]
10. Lack of CD44 variant 6 expression in advanced extrahepatic bile duct/ampullary carcinoma.
Yokoyama Y; Hiyama E; Murakami Y; Matsuura Y; Yokoyama T
Cancer; 1999 Nov; 86(9):1691-9. PubMed ID: 10547541
[TBL] [Abstract][Full Text] [Related]
11. Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis.
Joo M; Lee HK; Kang YK
Anticancer Res; 2003; 23(2B):1581-8. PubMed ID: 12820426
[TBL] [Abstract][Full Text] [Related]
12. Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor.
Hirata T; Fukuse T; Naiki H; Hitomi S; Wada H
Cancer Res; 1998 Mar; 58(6):1108-10. PubMed ID: 9515789
[TBL] [Abstract][Full Text] [Related]
13. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
Nguyen VN; Mirejovský T; Melinová L; Mandys V
Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
[TBL] [Abstract][Full Text] [Related]
14. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
Afify A; Lynne LC; Howell L
Diagn Cytopathol; 2007 Feb; 35(2):105-10. PubMed ID: 17230576
[TBL] [Abstract][Full Text] [Related]
15. CD44 and its v6 spliced variant in lung tumors: a role in histogenesis?
Fasano M; Sabatini MT; Wieczorek R; Sidhu G; Goswami S; Jagirdar J
Cancer; 1997 Jul; 80(1):34-41. PubMed ID: 9210706
[TBL] [Abstract][Full Text] [Related]
16. Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia.
Eisterer W; Bechter O; Söderberg O; Nilsson K; Terol M; Greil R; Thaler J; Herold M; Finke L; Günthert U; Montserrat E; Stauder R
Leuk Res; 2004 Oct; 28(10):1043-51. PubMed ID: 15289016
[TBL] [Abstract][Full Text] [Related]
17. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma.
Diaz LK; Zhou X; Wright ET; Cristofanilli M; Smith T; Yang Y; Sneige N; Sahin A; Gilcrease MZ
Clin Cancer Res; 2005 May; 11(9):3309-14. PubMed ID: 15867228
[TBL] [Abstract][Full Text] [Related]
18. Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy.
Chang SM; Xing RD; Zhang FM; Duan YQ
Oral Dis; 2009 Nov; 15(8):570-2. PubMed ID: 19563418
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of T antigen expression in patients with gastric carcinoma.
Chung YS; Yamashita Y; Kato Y; Nakata B; Sawada T; Sowa M
Cancer; 1996 May; 77(9):1768-73. PubMed ID: 8646672
[TBL] [Abstract][Full Text] [Related]
20. Altered CD44 variant 6 expression in FIGO stage IB cervical carcinoma.
Ayhan A; Baykal C; Al A; Ayhan A
Gynecol Oncol; 2001 Dec; 83(3):569-74. PubMed ID: 11733974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]